Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights

Study of ZIO-101 in Multiple Myeloma

Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information

Basic Trial Information

Phase
Type
Status
Age
Sponsor
Protocol IDs

Phase II, Phase I

Treatment

Closed

18 and over

Pharmaceutical / Industry

SGL2001
NCT00303199

Trial Description

Summary

The study of safety of a new organic arsenic compound in the treatment of advanced multiple myeloma

Eligibility Criteria

Subjects with multiple myeloma who have received at least two prior therapies and currently require therapy.

Trial Contact Information

Trial Lead Organizations/Sponsors

Ziopharm Oncology, Incorporated

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00303199
Information obtained from ClinicalTrials.gov on August 25, 2008

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.